Results 301 to 310 of about 264,642 (338)

Evaluation of PD-L1 Expression in Patients With Non-Small Cell Lung Cancer Using DCE-MRI Quantitative Analysis. [PDF]

Clin Respir J
Yang C, Zhu F, Li Q, Sun C, Jin H, Zhao Z.   +5 more
europepmc   +1 more source

Is Laparoscopic/Robotic Total Gastrectomy a Reasonable and Adequate Treatment for Proximal Advanced Gastric Cancer?

Annals of Gastroenterological Surgery, EarlyView.
Although the level of evidence is not high, this review indicates that laparoscopic total gastrectomy for advanced gastric cancer can be safely performed with the progress of surgical techniques, and there is little risk of worsening survival outcomes.
Takahiro Kinoshita, Masahiro Yura, Mitsumasa Yoshida, Daiki Terajima   +3 more
wiley   +1 more source

Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Wang CH, Chen SL, Yang X, Wu T, Liu LL, Yun JP.   +5 more
europepmc   +1 more source

Integrating Immune Checkpoint Inhibitors With Total Neoadjuvant Therapy in Proficient Mismatch Repair Rectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
The key to unlocking ICI benefit in pMMR/MSS LARC is to convert “cold” tumors into “hot” ones through lymphocyte‐sparing SCRT and judicious chemotherapy, creating a milieu in which ICIs can act effectively. ABSTRACT The management of locally advanced rectal cancer (LARC) has evolved with the adoption of total neoadjuvant therapy (TNT), integrated ...
Yoshinori Kagawa, Jun Watanabe, Koji Ando, Caleah Kitchens, Aron Bercz, J. Joshua Smith   +5 more
wiley   +1 more source

¹⁸F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients. [PDF]

EJNMMI Res
Grkovski M, Daras M, Bale T, Lyashchenko S, Reiner AS, Mellinghoff IK, Schöder H, Dunphy MPS.   +7 more
europepmc   +1 more source

Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Nivolumab‐including chemotherapy (nivo‐CTX) for stage IV gastric cancer (GC) may increase the chance of conversion surgery but risk of immune‐related adverse events (irAEs) during perioperative period remains unclear. Methods We examined irAEs in 36 patients with marginally resectable GC who received nivo‐CTX followed by surgery ...
Masashi Nishino, Takaki Yoshikawa, Hirokazu Shoji, Yuki Takenaka, Maho Takuwa, Yurina Fujisaki, Rei Ogawa, Takeyuki Wada, Tsutomu Hayashi, Yukinori Yamagata, Nobuyoshi Hiraoka, Yasuyuki Seto   +11 more
wiley   +1 more source

The JAK2 46/1 haplotype influences PD-L1 expression.

Blood
Carreño-Tarragona G, Tiana M, Rouco R, Leivas A, Victorino J, García-Vicente R, Chase AJ, Maidana A, Tapper WJ, Ayala R, Cross NCP, Martínez-López J, Manzanares M.   +12 more
europepmc   +1 more source

Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report. [PDF]

Front Oncol
Yu X, Zhao W, Feng Q, Tian J, Zhao L, Xiao J, Wei H.   +6 more
europepmc   +1 more source

Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review

Annals of Gastroenterological Surgery, EarlyView.
We systematically reviewed conversion therapy for esophageal squamous cell carcinoma and propose a response‐based treatment strategy for cT4b and M1 disease. For cT4b, we emphasize definitive chemoradiotherapy with timed re‐evaluation and selective salvage or chemoselection to surgery; for M1, conversion is reserved for limited‐burden responders with ...
Eisuke Booka, Hiroya Takeuchi
wiley   +1 more source

Extracellular Vesicles and PD-L1-A Review of Complex Immunoregulatory Properties and Clinical Importance. [PDF]

Biomedicines
Kiełbowski K, Plewa P, Szulc J, Ćmil M, Bakinowska E, Pawlik A.   +5 more
europepmc   +1 more source